Published in Nat Rev Endocrinol on March 01, 2010
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly (2008) 1.52
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res (2009) 1.13
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Official positions of the International Society for Clinical Densitometry. J Clin Densitom (2004) 3.63
Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 3.11
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom (2005) 2.44
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom (2008) 2.21
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res (2012) 1.77
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause (2013) 1.47
Algorithm for the management of osteoporosis. South Med J (2010) 1.45
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.35
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther (2002) 1.27
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.21
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab (2010) 1.12
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Efficacy and safety of monthly ibandronate in men with low bone density. Bone (2010) 1.04
Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom (2006) 1.03
Safety of bisphosphonates in the treatment of osteoporosis. Am J Med (2009) 1.02
Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin (2005) 1.01
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res (2004) 1.00
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab (2013) 0.98
Skeletal health in long-duration astronauts: nature, assessment, and management recommendations from the NASA Bone Summit. J Bone Miner Res (2013) 0.98
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone (2006) 0.94
Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 0.94
Is it ethical to use placebos in osteoporosis trials? J Clin Densitom (2006) 0.91
Standards for performing DXA in individuals with secondary causes of osteoporosis. J Clin Densitom (2006) 0.91
Summary of the International Society For Clinical Densitometry 2005 Position Development Conference. J Bone Miner Res (2007) 0.89
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab (2007) 0.89
Official positions of the International Society for Clinical Densitometry. Osteoporos Int (2006) 0.88
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom (2008) 0.88
Official positions of the International Society for Clinical Densitometry. South Med J (2004) 0.85
Update on romosozumab : a humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther (2014) 0.84
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab (2015) 0.84
In the clinic. Osteoporosis. Ann Intern Med (2011) 0.84
International Society for Clinical Densitometry official positions: Asia-Pacific Region consensus. J Clin Densitom (2010) 0.82
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Position Development Conference of the International Society for Clinical Densitometry. Vancouver, BC, July 15-17, 2005. J Rheumatol (2006) 0.81
Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol (2015) 0.80
Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry. J Clin Densitom (2007) 0.80
The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. Curr Opin Nephrol Hypertens (2015) 0.78
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother (2005) 0.78
Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis (2009) 0.78
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. Endocr Pract (2016) 0.77
Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. J Clin Densitom (2007) 0.77
An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care (2007) 0.77
Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry. J Clin Densitom (2007) 0.77
Impact of using the ultradistal radius region of interest on diagnostic classification. J Clin Densitom (2004) 0.77
Augmentation procedures for osteoporotic vertebral fractures--an ongoing experiment or emerging standard of care? South Med J (2006) 0.77
Bone-density testing interval and transition to osteoporosis. N Engl J Med (2012) 0.77
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. Endocr Pract (2016) 0.77
Sclerostin and skeletal health. Rev Endocr Metab Disord (2015) 0.76
The evolution of fracture risk estimation. J Bone Miner Res (2010) 0.76
Peripheral bone densitometry: Clinical applications. Arq Bras Endocrinol Metabol (2006) 0.76
Proceedings of the 5th annual perspectives in rheumatic diseases. Semin Arthritis Rheum (2013) 0.76
A review of strontium ranelate and its effect on DXA scans. J Clin Densitom (2007) 0.76
Medications don't work if patients don't take them. South Med J (2007) 0.75
Skeletal health prognostications. South Med J (2006) 0.75
Is it time for physicians to focus on the public health threat of gun violence? Ann Intern Med (2013) 0.75
Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol (2014) 0.75
Recommendations regarding individuals in whom bone densitometry should be performed: comment on the article by van Staa et al. Arthritis Rheum (2004) 0.75
Firearm-related injury and death in the United States. Ann Intern Med (2015) 0.75
Phytoestrogens and their role in the management of postmenopausal osteoporosis. South Med J (2009) 0.75
Vitamin D and common sense. J Clin Densitom (2011) 0.75
Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis? Curr Med Res Opin (2011) 0.75
Bone density testing to monitor osteoporosis therapy in clinical practice. Am Fam Physician (2010) 0.75